Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · AUROPHARMA

AUROB.PHARMA

HealthcarePharmaceuticals & Biotechnology₹103625 cr market cap
₹1805.70 ▲ +0.52% today As of 19 Nov 2026
52-week low ₹1121.7052-week high ₹1855.30

-3.2% from the 52-week high · +60.1% above the low

Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 15,690 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.

The short version. AUROB.PHARMA reported revenue of ₹10,263 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹1,126 crore (up 32.8% year on year). Return on equity was 9.2% in Mar 2026. Promoter holding was 51.87% in Sep 2026, up 0.05 points over 8 quarters.

1 · The price

How has the stock traded?

AUROB.PHARMA trades 3.2% below its 52-week high and 60.1% above its 52-week low.

Change over period: —

1M+10.8%
3M+10.6%
6M+18.4%
1Y+44.9%

2 · The business

Is it growing?

Sales, year on year+23.9%

Sep 2026 revenue of ₹10,263 cr.

Profit, year on year+32.8%

Sep 2026 net profit of ₹1,126 cr.

Net margin11.0%

0.8 pts higher than a year earlier.

3-year growth22.1% profit

Revenue compounded at 10.7% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue102639150885386468286786883827979
Net profit11261033921910848825903846
Net margin %11.011.310.410.510.210.510.810.6
EPS (₹)19.5717.9515.8615.6714.6114.215.5614.56

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue3365331724290022485523455247752309819564
Net profit35053486317319282648533528312365
Net margin %10.411.010.97.811.321.512.312.1
EPS (₹)60.3460.0254.1532.945.291.0548.3240.36

3 · The quality

How well does it turn capital into profit?

Return on equity was 9.2% in Mar 2026; debt to equity is 0.20.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %9.210.710.67.2
Return on capital %13.615.814.39.7
EBITDA margin %21.322.321.015.9
Net margin %10.310.810.77.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR10.7%6.3%
Profit CAGR22.1%-8.1%
Debt to equity0.20
Interest cover14.3x
Current ratio1.81
P/E ratio27.3

4 · The owners

Who holds it, and are they adding?

Promoter holding51.87%

Up 0.05 pts over 8 quarters.

Foreign institutions17.41%

Up 1.12 pts over 8 quarters.

Domestic institutions24.42%

Down 0.78 pts over 8 quarters.

Mutual fund schemes279

+53 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter51.8251.8251.8251.8251.8251.8251.8851.87+0.05
FII16.2915.3314.3714.2113.9415.2416.3817.41+1.12
DII25.226.2326.9327.627.6825.8725.124.42-0.78
Public6.696.616.876.386.557.086.646.29-0.4

Mutual fund holdings · Oct 2026

279 schemes hold this stock

226 the month before.

  • quant Manufacturing Fund10.2% of NAV
  • quant Mid Cap Fund10.14% of NAV
  • quant Dynamic Asset Allocation Fund10.06% of NAV
  • quant Multi Cap Fund9.94% of NAV
  • quant Momentum Fund9.92% of NAV
  • quant Large & Mid Cap Fund9.86% of NAV
  • quant Healthcare Fund9.83% of NAV
  • quant Business Cycle Fund9.7% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for AUROB.PHARMA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about AUROB.PHARMA

What is the AUROB.PHARMA share price?

AUROB.PHARMA (AUROPHARMA) last closed at ₹1,805.70, up 0.52% on the day. Its 52-week range is ₹1,121.70 to ₹1,855.30.

What is the market cap of AUROB.PHARMA?

AUROB.PHARMA has a market capitalisation of about ₹103,625 crore. Its price-to-earnings ratio is 27.3.

How are AUROB.PHARMA's latest results?

AUROB.PHARMA reported revenue of ₹10,263 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹1,126 crore (up 32.8% year on year). Return on equity was 9.2% in Mar 2026. Promoter holding was 51.87% in Sep 2026, up 0.05 points over 8 quarters.

Who owns AUROB.PHARMA?

As of Sep 2026, shareholding was: Promoter 51.87%, FII 17.41%, DII 24.42%, Public 6.29%.

How many mutual funds hold AUROB.PHARMA?

279 mutual fund schemes held AUROB.PHARMA in October 2026. That compares with 226 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 08 Aug 2025 · Interim Dividend - Rs. 4
  • 20 Feb 2024 · Interim Dividend - Rs. 1.5
  • 20 Nov 2023 · Interim Dividend - Rs. 3
  • 17 Feb 2023 · Interim Dividend - Rs. 3
  • 06 Jun 2022 · Interim Dividend - Rs. 4.5
  • 18 Feb 2022 · Interim Dividend - Rs. 1.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.